Global  

Matinas BioPharma sees positive outcome on End of Phase 2 meeting with FDA on MAT9001's development to treat severe hypertriglyceridemia

Proactive Investors Tuesday, 15 September 2020
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced Tuesday a positive result of its End of Phase 2 meeting with the US Food and Drug Administration (FDA) on the development and registration pathway for MAT9001, a potential best-in-class prescription omega-3 therapy.  The company said the official minutes of the meeting confirmed that it and the FDA are aligned on key next steps for MAT9001’s Phase 3 development program and registration pathway for an initial indication to treat severe hypertriglyceridemia (SHTG), a clinical disorder associated with major complications such as pancreatitis and atherosclerotic cardiovascular disease.  Matinas, based in Bedminster, New Jersey, said it remains on track to initiate its Phase 3 program in the first half of 2021. READ: Matinas BioPharma taps industry veteran Natasha Giordano as board director “We are extremely pleased with the outcome of our meeting with FDA and are encouraged by the highly collaborative and strategic input we received for our program,” said Theresa Matkovits, Matinas’ chief development officer, in a statement.  “I am very proud of what we have accomplished as a team and look forward to initiating the Phase 3 trial in SHTG and maximize the clinical opportunities for MAT9001.” The company said it and the FDA agreed on key elements of the Phase 3 program to support a New Drug Application (NDA) filing, including the requirement for a single 12-week study to support efficacy in SHTG.  Moreover, Matinas said the FDA provided it flexibility in the totality of patient safety data needed to meet regulatory requirements for NDA submission. The company is evaluating several ways to both meet these requirements and to potentially provide additional data differentiating MAT9001 from other prescription omega-3 drugs. “Alignment with the FDA on our Phase 3 development program provides clarity about our development pathway for MAT9001 in SHTG,” said Matinas CEO Jerome Jabbour. “With this important feedback from FDA, we can confidently move forward with our streamlined 505(b)2 registration for MAT9001. Our level of enthusiasm for this potential best-in-class omega-3 therapy remains high, and we look forward to forthcoming near-term data from our ongoing ENHANCE-IT head to head trial of MAT9001 vs. Vascepa to once again highlight the differentiation between these two products and the potential significant clinical benefits of MAT9001 for patients with hypertriglyceridemia and cardiovascular disease.” Contact the author: [email protected] Follow him on Twitter @PatrickMGraham    
0
shares
ShareTweetSavePostSend
 
Video Credit: CBS4 Miami - Published
News video: Protesters Take To Streets Of Broward, Miami-Dade Over Decision To Keep Bars Out Of Phase 2 Reopening

Protesters Take To Streets Of Broward, Miami-Dade Over Decision To Keep Bars Out Of Phase 2 Reopening 03:43

CBS4's Joan Murray reports on the frustrations from bar owners and employees.

You Might Like


Related videos from verified sources

Bihar polls: 52.24% voter turnout recorded in phase 1 till 5 pm [Video]

Bihar polls: 52.24% voter turnout recorded in phase 1 till 5 pm

Chief Election Commissioner Sunil Arora on October 28 informed about the voter turnout in the first phase of the Bihar polls. He said that voter turnout of 52.24 per cent recorded till 5 pm in the..

Credit: ANI     Duration: 01:29Published
Bihar polls 2020: Voting for first phase underway; over 1,000 candidates in fray [Video]

Bihar polls 2020: Voting for first phase underway; over 1,000 candidates in fray

First phase of polling in the three-phase Bihar Assembly Elections is underway. Over 1,000 candidates are in the fray for this phase. This election is India's first after the outbreak of Covid-19. The..

Credit: HT Digital Content     Duration: 01:31Published
Markets open in green, crucial GST council meeting today [Video]

Markets open in green, crucial GST council meeting today

Equity benchmark indices were up with a slight positive bias on Monday ahead of crucial Goods and Services Tax (GST) Council meeting to be chaired by Union Finance Minister Nirmala Sitharaman. At 10:10..

Credit: ANI     Duration: 01:11Published

Tweets about this